Ignite Creation Date:
2024-05-06 @ 8:20 AM
Last Modification Date:
2024-10-26 @ 11:59 AM
Study NCT ID:
NCT02718859
Status:
COMPLETED
Last Update Posted:
2019-09-12
First Post:
2016-03-09
Brief Title:
Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer
Sponsor:
Fuda Cancer Hospital Guangzhou
Organization:
Fuda Cancer Hospital Guangzhou
Study Overview
Official Title:
Study of the Combined Therapy of Irreversible ElectroporationIRE and Nature Killer NK Cells for Advanced Pancreatic Cancer
Status:
COMPLETED
Status Verified Date:
2019-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of the combined therapy using irreversible electroporationIREand nature killerNK cells for advanced pancreatic cancer
Detailed Description:
By enrolling patients with pancreatic cancer adapted to enrolled criteria this study will document for the first time the safety and the short and long term efficacy of the combined therapy using irreversible electroporationIREand nature killerNK cells for advanced pancreatic cancer
The efficacy will be evaluated according to relief degreeprogress free survivalPFS and overall survivalOS
The safety will be evaluated by statistics of adverse reaction
The efficacy will be evaluated according to relief degreeprogress free survivalPFS and overall survivalOS
The safety will be evaluated by statistics of adverse reaction
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None